# An Observational Study on Long-Term Efficacy and Safety of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (FAct)

> **NCT01483326** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 215 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01483326
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12-31
- **Primary completion:** 2017-06-19
- **Final completion:** 2017-06-19
- **Target enrollment:** 215 (ACTUAL)
- **Last updated:** 2019-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01483326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01483326, "An Observational Study on Long-Term Efficacy and Safety of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (FAct)". Retrieved via MORVS 2026-10-09 from https://api.morvs.ai/clinical/NCT01483326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*